Rosenberg, Jonathan E.

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature

Cancer Immunotherapy and BiomarkersTGF-β signaling in diseases

Cited by 5,400

Tumor mutational load predicts survival after immunotherapy across multiple cancer types

Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics

Cancer Immunotherapy and BiomarkersCancer Genomics and Diagnostics

Cited by 4,071

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 3,669

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 2,199

Pneumonitis in Patients Treated With Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy

Naidoo, J., Wang, X., Woo, K. M., Iyriboz, T., Halpenny, D., Cunningham, J., Chaft, J. E., Segal, N. H., Callahan, M. K., Lesokhin, A. M., et al. (2017) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersInterstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Cited by 1,215

Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers

Teo, M. Y., Seier, K., Ostrovnaya, I., Regazzi, A. M., Kania, B. E., Moran, M. M., Cipolla, C. K., Bluth, M. J., Chaim, J., Al-Ahmadie, H., et al. (2018) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 544

Phase I Clinical Trial of the CYP17 Inhibitor Abiraterone Acetate Demonstrating Clinical Activity in Patients With Castration-Resistant Prostate Cancer Who Received Prior Ketoconazole Therapy

Ryan, C. J., Smith, M. R., Fong, L., Rosenberg, J. E., Kantoff, P., Raynaud, F., Martins, V., Lee, G., Kheoh, T., Kim, J., et al. (2010) · Journal of Clinical Oncology

Prostate Cancer Treatment and ResearchBone health and treatments

Cited by 396

Treatment Outcomes of Immune-Related Cutaneous Adverse Events

Phillips, G. S., Wu, J., Hellmann, M. D., Postow, M. A., Rizvi, N. A., Freites-Martinez, A., Chan, D., Dusza, S., Motzer, R. J., Rosenberg, J. E., et al. (2019) · Journal of Clinical Oncology

Cancer Immunotherapy and BiomarkersChemotherapy-related skin toxicity

Cited by 241

Development of genome-derived tumor type prediction to inform clinical cancer care

Penson, A., Camacho, N., Zheng, Y., Varghese, A. M., Al-Ahmadie, H., Razavi, P., Chandarlapaty, S., Vallejo, C. E., Vakiani, E., Gilewski, T., et al. (2020) · JAMA Oncology

Cancer Genomics and DiagnosticsCancer Diagnosis and Treatment

Cited by 115

Polygenic risk for skin autoimmunity impacts immune checkpoint blockade in bladder cancer

Khan, Z., Di Nucci, F., Kwan, A., Hammer, C., Mariathasan, S., Rouilly, V., Carroll, J., Fontes, M., Ley Acosta, S., Guardino, E., et al. (2020) · Proceedings of the National Academy of Sciences

Cancer Immunotherapy and BiomarkersBladder and Urothelial Cancer Treatments

Cited by 91